Science Links Japan | Antiproteinuric Effect of an L/N-type Calcium Channel Blocker, Cilnidipine, with Special Reference to the Combination Therapy with ACE Inhibitors or ARBs

Antiproteinuric Effect of an L/N-type Calcium Channel Blocker, Cilnidipine, with Special Reference to the Combination Therapy with ACE Inhibitors or ARBs

Accession number;06A0673877

Title;Antiproteinuric Effect of an L/N-type Calcium Channel Blocker, Cilnidipine, with Special Reference to the Combination Therapy with ACE Inhibitors or ARBs

Author; TSUCHIHASHI TAKUYA (National Hospital Organization, Kyushu Medical Center, JPN) UENO MICHIO (National Hospital Organization, Kyushu Medical Center, JPN) TOMINAGA MITSUHIRO (National Hospital Organization, Kyushu Medical Center, JPN) KAJIOKA TOMOKO (National Hospital Organization, Kyushu Medical Center, JPN) ONAKA URAN (National Hospital Organization, Kyushu Medical Center, JPN) GOTO KEN'ICHI (National Hospital Organization, Kyushu Medical Center, JPN) OTA YUKO (National Hospital Organization, Kyushu Medical Center, JPN) ETO KIMIKA (National Hospital Organization, Kyushu Medical Center, JPN)

Journal Title;Ther Res

Journal Code:Y0681A

ISSN:0289-8020

VOL.27;NO.8;PAGE.1597-1603(2006)

Figure&Table&Reference;FIG.4, TBL.2, REF.31

Pub. Country;Japan

Language;Japanese

Abstract;We investigated the long-term antiproteinuric effect of an L/N-type calcium channel (Ca) blocker, cilnidipine in the patients with essential hypertension (EHT). Subjects are 37 EHT patients (61 .+-. 2 (SE) years, 22 females and 15 males). All patients underwent 24-h home urine collection and proved to have proteinuria greater than 0.1 g/day. Cilnidipine at a mean dose of 8 mg was administered to the patients. In 30 patients, cilnidipine was switched from other Ca antagonists including manidipine and amlodipine, while cilnidipine was newly added in the other 7 patients. Seventeen patients have been received either ACE inhibitors (ACEI) or ARBs at least 6 months before the administration of cilnidipine. Blood pressure (BP), blood chemistry and 24-h home urine collection were determined at 6, 12 and 24 months after the administration of cilnidipine. Baseline BP was 142 .+-. 2/85 .+-. 1 mmHg. Systolic BP did not change significantly throughout the study, while diastolic BP was significantly lower at 6 months (82 .+-. 1 mmHg, p<0.01), 12 months (84 .+-. 1 mmHg, p<0.05) and 24 month s(82 .+-. 2 mmHg, p<0.05). Urinary protein excretion decreased significantly from 0.36 .+-. 0.04 g/day to 0.16 .+-. 0.02 g/day(-45.7 .+-. 6.7%, p<0.01) at 6 months and to 0.14 .+-. 0.04g/day(-57.8 .+-. 12.0%, p< 0.01) at 12 months. The reduction of proteinuria occurred independently of the changes in BP. Urinary salt excretion, estimated protein intake, and serum creatinine concentration did not change significantly during the observation period. The reduction of proteinuria at 6 months after cilnidipine was similar between the patients with the baseline administration of ACEI/ARB (-47.6 .+-. 11.2%, p<0.01) and those without ACEI/ARB (-44.4 .+-. 8.7 %, p<0.01). On the other hand, the reduction of proteinuria continued until 24 months in the patients with ACEI/ARB (-41.1 .+-. 16.3 %, p<0.05) but not in those without ACEI/ARB (-9.3 .+-. 49.1%, ns).... (author abst.)

Related Articles;